Breakthrough in Alzheimer's Research: Lithium Deficiency May Be an Early Key Driver

A research team from Harvard Medical School and collaborating institutions recently published a major study in the journal Nature, revealing that endogenous lithium in the brain is closely linked to the pathogenesis of Alzheimer’s disease.

The findings demonstrate that lithium deficiency may represent a critical trigger in the early stages of the disease. Furthermore, supplementing with specific lithium compounds was shown to alleviate related pathologies in animal models.

By analyzing hundreds of brain and blood samples across healthy adults, individuals with mild cognitive impairment (MCI), and Alzheimer’s patients, the researchers identified lithium as the sole trace metal that exhibits a significant, selective depletion in the early stages of cognitive decline.

During the initial phase of memory deterioration, brain lithium levels drop markedly. As amyloid-beta (Aβ) plaques accumulate, they trap and bind lithium, depleting its bioavailability to surrounding neurons and consequently accelerating neurodegeneration.

In transgenic mouse models, lithium deficiency precipitated a cascade of neurodegenerative hallmarks: massive accumulation of amyloid-beta and tau proteins, heightened neuroinflammation, aberrant immune cell activation, synaptic damage, and myelin sheath thinning, leading to severe declines in learning and spatial memory.

The team subsequently evaluated lithium orotate—a compound capable of bypassing amyloid-beta binding. Administered at minute, physiological doses mirroring natural brain concentrations, this formulation successfully restored cerebral lithium levels, reversed Aβ/tau pathology, and rescued cognitive deficits in mice without inducing detectable toxicity or adverse side effects.

Study senior author Bruce A. Yankner emphasized that because these findings stem from postmortem tissue analyses and preclinical animal models, rigorous human clinical trials have yet to be conducted. Experts strongly advise against self-medicating with over-the-counter lithium supplements, as therapeutic windows, dosing, and drug interactions require strict clinical supervision. Excessive lithium intake carries significant risks of toxicity, particularly impacting thyroid and renal function.

If validated in forthcoming clinical trials, this breakthrough could pave the way for two major clinical applications: routine brain or blood lithium profiling as an early risk-screening biomarker, and targeted low-dose lithium regimens for Alzheimer’s prevention and intervention.

For individuals seeking to bolster brain health today, clinicians advise focusing on a balanced, nutrient-dense diet rich in antioxidants, omega-3 fatty acids, and essential vitamins—found in salmon, blueberries, spinach, and walnuts—which have well-established benefits for cognitive longevity. Anyone considering lithium supplementation must consult a qualified physician and await conclusive clinical trial outcomes.

Source: Aron, L., et al. (2025) Lithium deficiency and the onset of Alzheimer’s disease, Nature.